Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 9;22(1):61.
doi: 10.1186/s13058-020-01296-5.

Triple-negative breast cancer molecular subtyping and treatment progress

Li Yin  1   2   3 , Jiang-Jie Duan  1   2   3 , Xiu-Wu Bian  2   3 , Shi-Cang Yu  4   5   6
Affiliations
Review

Triple-negative breast cancer molecular subtyping and treatment progress

Li Yin et al. Breast Cancer Res. .

Abstract

Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER-2), has clinical features that include high invasiveness, high metastatic potential, proneness to relapse, and poor prognosis. Because TNBC tumors lack ER, PR, and HER2 expression, they are not sensitive to endocrine therapy or HER2 treatment, and standardized TNBC treatment regimens are still lacking. Therefore, development of new TNBC treatment strategies has become an urgent clinical need. By summarizing existing treatment regimens, therapeutic drugs, and their efficacy for different TNBC subtypes and reviewing some new preclinical studies and targeted treatment regimens for TNBC, this paper aims to provide new ideas for TNBC treatment.

Keywords: Molecular subtype; Therapeutic regimen; Therapeutic target; Triple-negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Progress in classification of TNBC molecular types, and interaction analysis of the Burstein four subtypes/FUSCC classification and Lehmann six subtypes, rectangle size varies in proportion to the number of samples [14, 19, 23]. AC, adenocarcinoma; ANC, anaplastic carcinoma; ASCC, acantholytic squamous cell carcinoma; CS, carcinosarcoma; DC, ductal carcinoma; IDC, invasive ductal carcinoma; IGA, invasive galactophoric adenocarcinoma; INF, inflammatory ductal carcinoma; MC, metaplastic carcinoma and MBC, medullary breast cancer
See this image and copyright information in PMC

References

    1. Torre LA, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. - PubMed
    1. Goldhirsch A, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–2223. - PMC - PubMed
    1. Wolff AC, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013. - PubMed
    1. Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. - PubMed
    1. Prat A, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24(Suppl 2):S26–S35. - PubMed

Publication types

MeSH terms